TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32289193
Drug: Well-being therapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-being therapy (WBT)
Study: 33710724
Drug: PECS II
Approvals — FDA: no, EMA: no, PMDA: no
Description: PECS II block with 30 mL 0.25% bupivacaine
Study: 33710724
Drug: RIB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIB with 30 mL 0.25% bupivacaine
Study: 616795279
Drug: Methylprednisolone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 0.5 mg/kg/tpd with beta-lactam plus macrolide
Study: 33961943
Drug: Hydroxychloroquine 300
Normalized name: hydroxychloroquine 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 300 mg once daily for 6 months
Study: 39463187
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly 400 mg (AOM 400)
Study: 33531062
Drug: Weekly sweep
Normalized name: sheep wool preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly sweep
Study: 37264472
Drug: Buprenorphine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine treatment
Study: 34033621
Drug: Caffeine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (4.5 mg·kg‐1)
Study: 32851257
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone
Study: 34674750
Drug: Bamlanivimab (4200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamlanivimab (4200 mg)
Study: 32467502
Drug: NOACs vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOACs vs Warfarin
Study: 33719027
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate hydrate (FC) 1000 mg/day
Study: 33719027
Drug: Ferric citrate
Normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric citrate hydrate (FC) 500 mg/day
Study: 33719027
Drug: Sodium ferrous
Normalized name: docusate sodium / ferrous fumarate Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium ferrous citrate (SF) 100 mg/day
Study: 35341944
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of Longevity™, a proprietary essential oil blend
Study: 33624184
Drug: Reldesemtiv 150
Normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reldesemtiv 150 mg
Study: 33624184
Drug: Reldesemtiv 450
Normalized name: Reldesemtiv
DrugBank: Reldesemtiv (DB15256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reldesemtiv 450 mg
Study: 33624184
Drug: Reldesemtiv (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reldesemtiv (highest peak plasma concentration quartile, Cmax > 3.29 μg/mL)
Study: 35724774
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg avasopasem
Study: 35724774
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg avasopasem
Study: 32129851
Drug: Targeted use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted use of ACTs and taking the correct dose, in addition to experience with RDT
Study: 33234634
Drug: GR1501 (IL-17A
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR1501 (IL-17A targeted monoclonal antibody)
Study: 39637881
Drug: Filgotinib 100
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Filgotinib 100 mg
Study: 39521467
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy
Study: 39289685
Drug: Oral synbiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral synbiotics
Study: 37452140
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg
Study: 616852759
Drug: High-frequency fulguration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency fulguration combined with 5% imiquimod cream
Study: 616852759
Drug: High-frequency fulguration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency fulguration combined with intramuscular injection of Bacillus Calmette-Guerin polysaccharide nucleic acid
Study: 35771569
Drug: BG00011 56
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG00011 56 mg once-weekly subcutaneous
Study: 34236302
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% patch (Laboratorios Gebro Pharma, SA)
Study: 34236302
Drug: Versatis 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Versatis 5% lidocaine patch (Grünenthal)
Study: 34808678
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment (Control)
Study: 32892756
Drug: Standardised lunch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardised lunch providing 1.5 g/kg body mass of carbohydrate
Study: 32383574
Drug: Motor program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor program activating therapy (Group 2)
Study: 33616765
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (G2) received treatment with OS and LED therapy (device turned off)
Study: 33616765
Drug: OS associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS associated with LED therapy (G5) once a week
Study: 33616765
Drug: OS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OS therapy plus infrared LED (G6) two sessions per week
Study: 32761980
Drug: Zembrin® (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zembrin® (25 mg)
Study: 35833120
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis MH‐02, 2 × 10^9 colony‐forming units per packet, once daily for 7 days
Study: 32649493
Drug: Tamoxifen 10
Normalized name: tamoxifen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 10 mg twice daily for 7 days after 3 consecutive days of bleeding or spotting
Study: 35671033
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with comorbidity
Study: 35671033
Drug: Metformin without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin without comorbidity
Study: 32302798
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with dementia undergoing oral and maxillofacial surgery
Study: 35244704
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and nicotine patch
Study: 33077259
Drug: Clear cell
Normalized name: Umbilical Cord Blood Mononuclear Cells Conditioned Medium
DrugBank: Human umbilical cord blood mononuclear cell-conditioned medium (DB15724)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear cell (CC) OC
Study: 32770640
Drug: Secukinumab 150
Normalized name: secukinumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg with a loading dose (LD group)
Study: 37574132
Drug: Alectinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alectinib 600 mg twice daily
Study: 35275991
Drug: Crizotinib 250
Normalized name: crizotinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib 250 mg
Study: 33481455
Drug: Inpatient physical
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient physical rehabilitation (4-week hospitalization with physical, occupational, and speech therapy)
Study: 34904190
Drug: Etomidate (0.2-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.2-0.3 mg/kg)
Study: 32286687
Drug: Adjuvant trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks
Study: 32286687
Drug: Trastuzumab 6
Normalized name: Trastuzumab 60 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab 6 mg/kg intravenously every 3 weeks
Study: 35685611
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol and remifentanil
Study: 33220395
Drug: E +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: E + RT (oral erlotinib 150 mg/d for 2 years or until disease progression or intolerable toxicity and RT 200 cGy/d, 5 d/wk for 6 weeks)
Study: 32550915
Drug: SC144 (gp130
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC144 (gp130 inhibitor)
Study: 32058426
Drug: Cariprazine low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cariprazine low-dose (0.25-0.5 mg/day)
Study: 32058426
Drug: Cariprazine high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine high-dose (1.5-3.0 mg/day)
Study: 35210111
Drug: Biodegradable gel
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biodegradable gel containing hyaluronic acid and berberine hydrochloride
Study: 33246499
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (2 units of 200 to 250 mL within 12 hours after randomization, with a second administration of 2 units 24 to 36 hours after the first administration)
Study: 35012326
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus psychological therapy
Study: 35012326
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg/kg i.v. over 40 minutes) plus alcohol education
Study: 35012326
Drug: Saline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline plus psychological therapy
Study: 33823966
Drug: Drug-associated cue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-associated cue exposure in abstinent MUD group
Study: 33823966
Drug: Scrambled trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scrambled trials (no drug-associated cues) in abstinent MUD group
Study: 35666728
Drug: Bronchodilators
Normalized name: ANTIASTHMA/BRONCHODILATORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilators
Study: 36963200
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment regimens
Study: 34115380
Drug: Monthly fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly fremanezumab (675 mg for CM, 225 mg for EM)
Study: 616173846
Drug: Trimetazidine (TR)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TR) 70 mg/d bid for 3 months, then Ranolazine (RN) 1000 mg/d bid for 3 months
Study: 616173846
Drug: Ranolazine (RN)
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine (RN) 1000 mg/d bid for 3 months, then Trimetazidine (TR) 70 mg/d bid for 3 months
Study: 34564022
Drug: 600 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/kg betaine (group B)
Study: 34564022
Drug: 1,200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg/kg betaine (group C)
Study: 34564022
Drug: 1,800 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 mg/kg betaine (group D)
Study: 39067509
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray
Study: 32082606
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray
Study: 33902551
Drug: SA (alumina
Approvals — FDA: no, EMA: no, PMDA: no
Description: SA (alumina sandblasted and acid‐etched) implants
Study: 37657525
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX monotherapy
Study: 34533841
Drug: Biperiden (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (4 mg)
Study: 36169608
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group 1: diprospan combined with mucopolysaccharide polysulphate cream
Study: 36169608
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group 2: isotopic phosphorus‐32 dressing combined with mucopolysaccharide polysulphate cream
Study: 36169608
Drug: Treatment Group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Group: isotopic phosphorus‐32 dressing combined with diprospan and mucopolysaccharide polysulphate cream
Study: 36503505
Drug: Negative Pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative Pressure Wound Therapy (NPWT)
Study: 32401733
Drug: Non-NPWT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-NPWT treatment (petrolatum gauze and Bogota bag)
Study: 35997729
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (IMRT with cisplatin, 100 mg/m2 every 3 weeks for 3 cycles) (n=169)
Study: 35997729
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (n=169)
Study: 34930386
Drug: Posttreatment CA-125
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttreatment CA-125 level > 10 U/ml
Study: 34930386
Drug: Posttreatment CA-125
Normalized name: Ca 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posttreatment CA-125 level ≤ 10 U/ml
Study: 33634319
Drug: Standard MNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard MNP (12.5 mg iron)
Study: 32749579
Drug: Carbonated water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbonated water (250 ml)
Study: 32749579
Drug: Plain water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain water (250 ml)
Study: 33326891
Drug: Antidepressant medications
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant medications
Study: 34240125
Drug: hs‐cTnI at
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs‐cTnI at 10 ng/L
Study: 34240125
Drug: hs‐cTnT at
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs‐cTnT at 10 ng/L
Study: 37865138
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone (XR-NTX)
Study: 35680097
Drug: Placebo (balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (balanced salt solution)
Study: 35349129
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of dexamethasone
Study: 32056766
Drug: Peer- or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer- or clinician-led group behavioral treatment for 20 weeks
Study: 36014767
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no glucoraphanin or alliin supplements)
Study: 37488627
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy
Study: 35193054
Drug: SCT630 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT630 (40 mg)
Study: 33619820
Drug: Cream applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream applied with expectation of pain reduction after 5 minutes (P5)
Study: 33619820
Drug: Cream applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream applied with expectation of pain reduction after 30 minutes (P30)
Study: 33619820
Drug: Cream with
Normalized name: CREAM WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream with no analgesic expectation (NE)
Study: 36479231
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) alone
Study: 35811600
Drug: Peer-led preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-led preventive oral health education
Study: 35811600
Drug: Class-based lecture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class-based lecture on oral health (Control)
Study: 39671076
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily
Study: 34665856
Drug: Salbutamol (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (24 mg oral)
Study: 35319669
Drug: Antibiotic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic group (GAtb) - 500 mg amoxicillin + 400 mg metronidazole
Study: 36459138
Drug: High-dose erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose erythropoietin
Study: 32981043
Drug: GONB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GONB with bupivacaine 0.5% (3 mL each side)
Study: 39606837
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available therapy
Study: 34848180
Drug: Intramuscular depot
Normalized name: Primoteston Depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular depot medroxyprogesterone acetate (DMPA‐IM)
Study: 33942167
Drug: NIPEC (Normothermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPEC (Normothermic Intraperitoneal Chemotherapy)
Study: 33942167
Drug: Standardized cytoreductive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized cytoreductive surgery and perioperative chemotherapy
Study: 36348313
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy counseling (8 systematic desensitization sessions, 2-3 sessions per week)
Study: 36348313
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy counseling
Study: 33865577
Drug: Ad libitum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad libitum rate of MR (ADLIB; offered twice daily for 35 d, 0.66 kg/d for 4 d, and 0.33 kg/d for 3 d)
Study: 33108521
Drug: Cod (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod (750 g/week)
Study: 32591326
Drug: Pharmaceutical training
Normalized name: PHARMACEUTICAL GLAZE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical training program without a communication component
Study: 35552673
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg orally/day; 3/1 week schedule) and Fulvestrant (500 mg intramuscularly)
Study: 35552673
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and Fulvestrant (500 mg intramuscularly)
Study: 32248591
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplementation (400 IU/d)
Study: 33189562
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of CDK4/6 inhibitors (CDK4/6i) beyond first disease progression (PD)
Study: 32783667
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors (CDK4/6i)
Study: 36881395
Drug: Beta-blocker
Normalized name: BETA-BLOCKERS,TOPICAL OPHTHALMIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker
Study: 32037380
Drug: Diuretic
Normalized name: Diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic
Study: 36293365
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Betula alba and Empetrum nigrum extracts
Study: 38385941
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg
Study: 36394498
Drug: Acceptance-Based Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-Based Therapy (ABT) intervention, 15 virtual, 90-minute group sessions.
Study: 36394498
Drug: Enhanced care,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced care, 15 healthy lifestyle handouts, met virtually twice with a registered dietitian.
Study: 33689702
Drug: CDK4/6 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitors (specific inhibitors not mentioned)
Study: 36065041
Drug: 6-week reactive
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week reactive agility training program using light-based stimuli (Witty SEM light stimulus), 60-min training sessions twice a week
Study: 35303509
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) delivered by the CyberKnife® system targeting resection margin one month after surgery; total dose of 35 Gy.
Study: 35303509
Drug: Surgery alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery alone (SA) group; no specific dosage mentioned.
Study: 33047417
Drug: Copayment elimination
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copayment elimination for cardioprotective medications
Study: 34774196
Drug: BBV152 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBV152 vaccine (two intramuscular doses administered 4 weeks apart)
Study: 34774196
Drug: BBV152 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBV152 vaccine
Study: 35511655
Drug: Lenoid™ topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenoid™ topical treatment
Study: 34262151
Drug: Strength or
Normalized name: Regular Strength Orajel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength or balance exercise during chemotherapy treatment
Study: 39283627
Drug: Erenumab 140
Normalized name: Erenumab 140 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 140 mg
Study: 37699636
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration
Study: 36189008
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control
Study: 35078841
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Conventional intravenous induction without topical anaesthesia)
Study: 32519032
Drug: Liquid 6MP
Normalized name: 2-Amino 6MP
DrugBank: Tioguanine (DB00352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid 6MP formulation (20 mg/ml)